Compare Amgen, Inc. (AMGN) vs American Express Co (AXP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs American Express Co — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while American Express Co trades at $344.7 (market cap $230.15B). The key difference: Amgen, Inc. and American Express Co are close in size by market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | AXP | |
|---|---|---|
Market Cap | $224.14B | $230.15B |
Sector | Health | Financials |
52-Week High | $417.20 | $384.82 |
52-Week Low | $271.18 | $292.27 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
AXP trades at $343.22, up 1.29% today, with a bullish technical signal and strong support at $339. The stock shows robust fundamentals with 2025 revenue of $72.23B and net income of $10.83B, though recent earnings have been mixed. Analyst consensus is a $369.42 price target with 40% buy ratings. Recent news highlights Amex Ventures' AI investments and premium cardmember benefits, reinforcing growth initiatives.
Outlook remains positive due to steady revenue growth and high ROE of 33.97%, but risks include competitive pressures and a P/E of 20.68 above sector averages. The stock offers upside to consensus targets if execution continues, though investors should monitor spending trends and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →
